Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Conditions
Interventions
SHR6508 plus oral placebo tablets
Cinacalcet plus intravenous placebo
Locations
1
China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Start Date
June 14, 2024
Primary Completion Date
September 29, 2025
Completion Date
November 11, 2025
Last Updated
December 12, 2025
NCT03633708
NCT04922892
NCT04064827
NCT02859896
NCT00415584
NCT01167309
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions